MG-132 化学構造
分子量: 475.62

高品質保証

文献中の引用(43)

カスタマーフィードバック(9)

Quality Control & MSDS

製品説明

  • Compare Proteasome Inhibitors
    Proteasome製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 MG-132は、100nMのIC50によるプロテアソームの強力な阻害剤です。
ターゲット

Proteasome

IC50

100 nM [1]

In vitro試験 MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
LPS-stimulated RAW264.7 cells Mo\tSpVv[3Srb36gRZN{[Xl? NEPOcYQzPSEQvF2= NFrCO|dFVVOR M2OzSWlvcGmkaYTzJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAxNjFizszN M4LvUFI1Pjl5NEm2
HL-60 M3\xNGN6fG:2b4jpZ{BCe3OjeR?= NEfCR2I1OCEQvF2= M{HBOlQ5KGh? MmO2SG1UVw>? Mo\MTWM2ODxzMDFOwG0> NXv1ZYJrOjR4OUe0PVY>
SMMC-7721 MYTDfZRwfG:6aXOgRZN{[Xl? M3f2W|QxKM7:TR?= MX:0PEBp Mn7BSG1UVw>? M{nnZWlEPTB;Nz6xJO69VQ>? MnryNlQ3QTd2OU[=
A-549 MmDVR5l1d3SxeHnjJGF{e2G7 NWHOSFZEPDBizszN MkjPOFghcA>? MmLvSG1UVw>? NIjEe2FKSzVyPEGwJO69VQ>? NGXC[2IzPDZ7N{S5Oi=>
MCF-7 NX;H[5hbS3m2b4TvfIlkKEG|c3H5 NXnZbYZMPDBizszN MYq0PEBp M1PqPGROW09? MXPJR|UxRTdwMzFOwG0> NI\yXnQzPDZ7N{S5Oi=>
SW-480 MlvtR5l1d3SxeHnjJGF{e2G7 NITa[W81OCEQvF2= NYrQN5pkPDhiaB?= MWLEUXNQ NELWVI5KSzVyPUSg{txO MWOyOFY6PzR7Nh?=
NCI-H929 NITWeppEgXSxdH;4bYMhSXO|YYm= MWSxJO69VQ>? Ml3nO|IhcA>? NFe1eWdFVVOR MX7JR|UxRTBwMUeg{txO MnzwNlQ3OjVyOEi=
293T NW\Nb2NFS3m2b4TvfIlkKEG|c3H5 MYCxNEDPxE1? NVTFSYNiPzJiaB?= NXjrNIN[TE2VTx?= NF6wVJhKSzVyPEKg{txO NHjhR3MzPDZ{NUC4PC=>
293T MWrGeY5kfGmxbjDBd5NigQ>? NXXzWHRVOTBizszN NWL3NJBGOjRiaB?= MXvEUXNQ MnPrUY9l\XKjdHXsfUBqdmS3Y3XzJIhm[XRvc3jvZ4shKA>? M3jTXFI1PjJ3MEi4
HeLa NWX4VGg2U2mwYYPlJGF{e2G7 M4r3dVExKM7:TR?= MWWxJIg> MULEUXNQ Ml3tTY5lfWOnczDQRXJRKGOuZXH2ZYdmKGK7IHnubIljcXSrbnegdJJwe2Wjc3;t[UBi[3Srdnn0fS=> M{G2[FI1OzJzOEOz
MDA-MB-231 NGjhWJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\Y[2RFOSEQvF2= NX7mVoxQPzJiaB?= NXS4XFFRTE2VTx?= NGDMXFNKSzVyPUCuNVgh|ryP M3rSR|I1OTV|MkC2
MCF-7 NXXLd3lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Ps[|Eh|ryP NGC1Umg4OiCq NUK4ToN3TE2VTx?= MWjJR|UxRTBwMUOg{txO NV70XXFUOjRzNUOyNFY>
MCF10A MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOxJO69VQ>? MkHlO|IhcA>? NWjJUmpiTE2VTx?= MoHWTWM2OD1yLkK5JO69VQ>? NHLpSpUzPDF3M{KwOi=>
HEK-293 NVXkTXVMU2mwYYPlJGF{e2G7 MV[yJIFv\CB{MDFOwG0> NF3UXHEzKGh? MXHEUXNQ NGHpbI1KdmirYnn0d{BEcFRvTDDhZ5Rqfmm2eTD3bZRpKEmFNUCgc4YhQSCwTTC= M2LNZ|I{PTRyN{mw
Calu6 NIjE[JdHfW6ldHnvckBCe3OjeR?= NUm4coRLOTBizszN NG\KO20yQCCq NYjQNmN[TE2VTx?= M3mzbXNq\26rZnnjZY51dHliYXPjeY12dGG2ZYOg[pJifGG6aX6gdJJm[3W{c3;y NVvOS4dJOjN3ME[0PFY>
IFN-gamma-induced RAW264.7 MWfGeY5kfGmxbjDBd5NigQ>? NFvyVFlFVVOR NYe1[5hRUW6qaXLpeJMhdmm2cnnjJI95cWSnIIDyc4R2[3Srb36ge4l1cCCLQ{WwJI9nKDBwMEe3JO69VQ>? MoTjNlIzPzd{N{e=
IPC227F NH\Ze2tEgXSxdH;4bYMhSXO|YYm= NVj2fZJpOSEQvF2= M4nX[|Q5KGh? MWjEUXNQ M13XeGlEPTB;MD6wO|ch|ryP Mn;UNlE6OjR3Mki=
Hepa-1c1c7 NYPEUHhCTnWwY4Tpc44hSXO|YYm= MlXWNlUh|ryP M2\GUlYhcA>? NX[wd4Z2TE2VTx?= MnHUTY5kemWjc3XzJG5z\jJicILveIVqdiCuZY\lcC=> M2K4b|IxOzl{NUS0
COS-7 NUXCTWxXS3m2b4TvfIlkKEG|c3H5 NUThNZYxOTBizszN NVz3Z3BwTE2VTx?= NYXZWnJkUUN3MEyxNEDPxE1? MlHRNVgxQDhyOUe=
HuH-7 M{jKO2N6fG:2b4jpZ{BCe3OjeR?= MljaNVAh|ryP MoD3SG1UVw>? MmLoTWM2ODxzMDFOwG0> NVLESW5tOThyOEiwPVc>
OCI-Ly3 NYC2bGlCTnWwY4Tpc44hSXO|YYm= NY\OOHhGOTBizszNxsA> MnTwOEBp NF\jUGtFVVOR MYPJcoR2[2W|IHj1cYFvKEmtYYDwZWJidHCqYTDzeIFjcWyrenH0bY9vKHerdHigSWM2OCCxZjCxJO69VQ>? NULyeFJEOThyMkSxNVM>
A2780 cDDP MmH0RZBweHSxc3nzJGF{e2G7 MVuyOEBp NGfVcnNFVVOR Mly3TY5lfWOnczDhdI9xfG:|aYOgZpkhcW6qaXLpeIlv\yCSVFXOJIRm\3KjZHH0bY9v MmK4NVc3QDRyMUi=
LPS-stimulated RAW264.7 cells Ml;YSpVv[3Srb36gRZN{[Xl? NYLtPZZXTE2VTx?= NXfLNnRSUW6qaXLpeJMhVkZva3HwdIFDKESQQTDibY5lcW6p Mo\hNVc1ODd{N{e=
PC12 MoXHSpVv[3Srb36gRZN{[Xl? MnHiNVAxKM7:TdMg MXGyOEBp MXvEUXNQ NYHid2NiUW6qaXLpeJMhPi2RSFTBMUBidmRiSELPNk1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? NX\wOWkzOTdzNUi0OVQ>
PC3 NH\JRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzLNlAh|ryP M3T1XVQ5KGh? NIHtb2VFVVOR NGfrWlRKSzVyPUCuOkDPxE1? NWX3cZQ2OTZ4OE[1N|c>
LP-1 MVfBdI9xfG:|aYOgRZN{[Xl? NEe0b|U{ODBibl2= M1:4ZlI1KGh? MlP6SG1UVw>? MlzsTY5lfWOnczDhdI9xfG:|aYOgZpkhcW6lcnXhd4lv\yClbHXheoVlKFCDUmCgcIV3\WxiYX7kJJJm\HWlaX7nJG1kdC1zIIDyc5RmcW5ibHX2[Yw> NU\zXpNYOTV7NUi1PFk>
ES6 NEHzZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLsRolKSzVyPUCuNFE{ODZizszN MnzvV2FPT0WU
A101D NIPkelZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L5TmlEPTB;MD6wN|I4QSEQvF2= MXPTRW5ITVJ?
OCUB-M Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:yTWM2OD1yLkCzO|M4KM7:TR?= NVPN[HFxW0GQR1XS
LB2518-MEL MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLlTWM2OD1yLkCzO|Yh|ryP MW\TRW5ITVJ?
SH-4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;3cmlEPTB;MD6wOFMyKM7:TR?= NHTFcIZUSU6JRWK=
KNS-42 NVe2[XdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi5TWM2OD1yLkC0OFQyKM7:TR?= MX3TRW5ITVJ?
DSH1 NYjhS49kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3yXZFKSzVyPUCuNFUzQDlizszN NFfEPXRUSU6JRWK=
NTERA-S-cl-D1 M3vOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M162SGlEPTB;MD6wOVc4OiEQvF2= MorUV2FPT0WU
D-542MG NETpcGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mln0TWM2OD1yLkC1PVU4KM7:TR?= NEXRSVBUSU6JRWK=
KS-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEW0ZopKSzVyPUCuNFY1PThizszN NES4N|dUSU6JRWK=
BL-41 M2[5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwME[5OFch|ryP NG\1eGhUSU6JRWK=
LXF-289 NUexR|FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMEewOlYh|ryP M3XkTHNCVkeHUh?=
D-247MG NFzEOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\u[ZlKSzVyPUCuNFczODlizszN MYDTRW5ITVJ?
MMAC-SF MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHuTWM2OD1yLkC3NlY5KM7:TR?= NIH5cm9USU6JRWK=
CP66-MEL NWTTVlB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn4[JlWUUN3ME2wMlA4PSEQvF2= MU\TRW5ITVJ?
LB771-HNC NFm3UVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\ReGlEPTB;MD6wPFA{PiEQvF2= NEXwR4tUSU6JRWK=
no-10 MojQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G3NWlEPTB;MD6wPFkxQSEQvF2= MWTTRW5ITVJ?
A388 MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMEmwOlUh|ryP M2Xtb3NCVkeHUh?=
OPM-2 M1rUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\ZTWM2OD1yLkGwOFc1KM7:TR?= MluwV2FPT0WU
OVCAR-4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;YZZB3UUN3ME2wMlExQTN6IN88US=> MofjV2FPT0WU
HOP-62 MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m2SWlEPTB;MD6xNFk1QSEQvF2= MV3TRW5ITVJ?
ML-2 NF3HNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD3TWM2OD1yLkGxPFA3KM7:TR?= MnvXV2FPT0WU
UACC-257 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMUG5Nlch|ryP MX7TRW5ITVJ?
NEC8 M3jmT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULMRYs5UUN3ME2wMlEyQTl3IN88US=> MYXTRW5ITVJ?
ONS-76 MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMUK5N|Uh|ryP NW\4WVcxW0GQR1XS
KE-37 NXrLO4tET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LPV2lEPTB;MD6xN|I4QCEQvF2= MUHTRW5ITVJ?
HT-144 NHizdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D4[WlEPTB;MD6xN|g6PSEQvF2= M2nSRnNCVkeHUh?=
LB2241-RCC NEX5eGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjW[nZRUUN3ME2wMlE1OjR5IN88US=> MYHTRW5ITVJ?
TE-5 MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjy[5B3UUN3ME2wMlE1Ojd6IN88US=> M3LkcXNCVkeHUh?=
KINGS-1 MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPlTWM2OD1yLkG0O|kh|ryP MYfTRW5ITVJ?
NCI-H69 NGDmTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXGUmJKSzVyPUCuNVUyPDFizszN NF;weVVUSU6JRWK=
CAS-1 M2K5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDkTWM2OD1yLkG1OFgzKM7:TR?= M3T1WHNCVkeHUh?=
D-263MG MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;vO2lEPTB;MD6xOlAxPiEQvF2= MnHqV2FPT0WU
A253 NWHCfJM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwMU[xNlgh|ryP MYjTRW5ITVJ?
PF-382 M2XLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMU[3NFYh|ryP Ml3GV2FPT0WU
CESS M2mw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLVTWM2OD1yLkG3NFYh|ryP NF\MR5ZUSU6JRWK=
MZ2-MEL M1rZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfVTWM2OD1yLkG3OVU6KM7:TR?= MmLDV2FPT0WU
HEL NUS0[VFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILaNm5KSzVyPUCuNVg2OTdizszN MYLTRW5ITVJ?
D-392MG M4PFfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTWXIhKSzVyPUCuNVkyOTVizszN M4rUdXNCVkeHUh?=
SK-LMS-1 NWPPeW4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwMUmzNFMh|ryP M{XiVnNCVkeHUh?=
GI-ME-N NWTsco5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwMUmzNFYh|ryP NG\qfYpUSU6JRWK=
LB831-BLC NGCyeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMUmzOEDPxE1? MXTTRW5ITVJ?
DU-4475 NF7ufVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkKzTWM2OD1yLkG5OlU5KM7:TR?= MkjxV2FPT0WU
IST-SL1 MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnHZ4czUUN3ME2wMlIxODl2IN88US=> NFfnZWtUSU6JRWK=
GAK MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILSVWFKSzVyPUCuNlA2OzRizszN NYfvO2R7W0GQR1XS
EW-1 NVnXTIhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFniV45KSzVyPUCuNlExPDdizszN NIPwOVBUSU6JRWK=
LAMA-84 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjlNlhKSzVyPUCuNlE5PTFizszN MYnTRW5ITVJ?
SK-UT-1 NVPGdlVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvXTINzUUN3ME2wMlIzODR7IN88US=> NFrVN4dUSU6JRWK=
VA-ES-BJ M4q2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwMkKyOVch|ryP M1GweHNCVkeHUh?=
ACN MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX4PGVKSzVyPUCuNlI3OzhizszN Mn3yV2FPT0WU
SK-PN-DW M1f5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMkOxPUDPxE1? M{ewSnNCVkeHUh?=
HD-MY-Z NFPpZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvCTWM2OD1yLkKzN|A{KM7:TR?= NITESGVUSU6JRWK=
LB373-MEL-D NXjOeogzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWK5dGZjUUN3ME2wMlI1OTl6IN88US=> NXvqSFZ6W0GQR1XS
COLO-829 MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3pTWM2OD1yLkK0NlU4KM7:TR?= NHzCS2RUSU6JRWK=
ES8 NX6wdYY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlOxTWM2OD1yLkK0O|Y{KM7:TR?= M1XuVXNCVkeHUh?=
RXF393 Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPv[4tSUUN3ME2wMlI2ODF3IN88US=> NEfRTFlUSU6JRWK=
TK10 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTsTWM2OD1yLkK1OFM2KM7:TR?= MojHV2FPT0WU
LOUCY NEPnO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfnTWM2OD1yLkK1OFU3KM7:TR?= Mm[yV2FPT0WU
MZ7-mel MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkGyTWM2OD1yLkK2N|c1KM7:TR?= M{jYeXNCVkeHUh?=
CP67-MEL M2XWS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMk[3N{DPxE1? NXm3WG1TW0GQR1XS
C2BBe1 NWLEN25LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrFdG9KSzVyPUCuNlc6ODdizszN NYnhOIJtW0GQR1XS
K052 Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml61TWM2OD1yLkK4PVkh|ryP M1P1R3NCVkeHUh?=
MOLT-16 M2nkVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLvcZF4UUN3ME2wMlI6PTJ2IN88US=> MnLKV2FPT0WU
KNS-81-FD NVXXNJppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDzTWM2OD1yLkOwN|I{KM7:TR?= NGn5eJJUSU6JRWK=
CMK M1vnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwM{GxNkDPxE1? MnPPV2FPT0WU
LAN-6 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnuPGFKSzVyPUCuN|E{KM7:TR?= NUjwXVZ1W0GQR1XS
KLE NVrUN5NyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7rTWM2OD1yLkOxN|A3KM7:TR?= MVTTRW5ITVJ?
NCCIT MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwM{G3PFMh|ryP MXfTRW5ITVJ?
HH MnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHyxZ|FKSzVyPUCuN|I5QTdizszN M{SwVHNCVkeHUh?=
TE-8 NGHaUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\MPW5MUUN3ME2wMlM1Ojd7IN88US=> MonsV2FPT0WU
GDM-1 NHvxdXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\n[ZdvUUN3ME2wMlM2OTB2IN88US=> NV7nVFdOW0GQR1XS
NCI-H747 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rvNGlEPTB;MD6zO|ExOyEQvF2= M{iwfHNCVkeHUh?=
NCI-H1092 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXy2Vo44UUN3ME2wMlM5QDR2IN88US=> M2T1SnNCVkeHUh?=
8-MG-BA MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPDephVUUN3ME2wMlM6QDN5IN88US=> NXnkN2hMW0GQR1XS
NB17 NGP4XZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTGTWM2OD1yLkSyPVch|ryP NYrRbVh4W0GQR1XS
LC4-1 M{TFe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XMS2lEPTB;MD60N|YxPyEQvF2= M{LTTXNCVkeHUh?=
TE-1 NFfWUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXTTWM2OD1yLkS1NVE6KM7:TR?= NXPQfJRTW0GQR1XS
KALS-1 MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG0b4FKSzVyPUCuOFY2QDRizszN NVzSe4c5W0GQR1XS
CCRF-CEM MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoCzTWM2OD1yLkS3Olc1KM7:TR?= MVnTRW5ITVJ?
OS-RC-2 NV\wRo13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzRbJduUUN3ME2wMlQ4QTd{IN88US=> MYPTRW5ITVJ?
A704 M3PObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwNEi2PVIh|ryP MX\TRW5ITVJ?
BB49-HNC MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn2wTWM2OD1yLkS5NFk3KM7:TR?= Mn3iV2FPT0WU
EVSA-T M2jvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTFTWM2OD1yLkS5PVEyKM7:TR?= NYTDcZRjW0GQR1XS
Mo-T M{DCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX5TWM2OD1yLkWxO|YzKM7:TR?= NIrtW3lUSU6JRWK=
MONO-MAC-6 M2nZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XxUmlEPTB;MD61N|YyOSEQvF2= Mnq4V2FPT0WU
BB65-RCC NF\zeoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPQTWM2OD1yLkW2PFEyKM7:TR?= M3XXWnNCVkeHUh?=
NCI-H1882 NUXSU5dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\nTWM2OD1yLkW5NFM3KM7:TR?= NYHGepdDW0GQR1XS
TE-9 NWX2VplxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\aXmd1UUN3ME2wMlYyODN|IN88US=> MlXyV2FPT0WU
NCI-H2126 NIfEe3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M16zPWlEPTB;MD62NlY3QSEQvF2= NH65VnZUSU6JRWK=
SF268 Mli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwNkW2OFEh|ryP NUfjO5hnW0GQR1XS
SW872 MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XuSWlEPTB;MD62OVczQSEQvF2= MV;TRW5ITVJ?
LS-513 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XkPWlEPTB;MD62Olc2OSEQvF2= M1TmfXNCVkeHUh?=
NCI-H1355 NEm3VopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HXVmlEPTB;MD62PFYyQSEQvF2= NXv4UHhFW0GQR1XS
BL-70 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzHb2NoUUN3ME2wMlY6Ozh6IN88US=> Mnr1V2FPT0WU
NCI-SNU-5 Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7ZT4hKSzVyPUCuOlk2PDVizszN Ml;MV2FPT0WU
SNU-C2B MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPvRYdLUUN3ME2wMlcxPzN7IN88US=> M2H3eXNCVkeHUh?=
GB-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4riZmlEPTB;MD63NlEzPCEQvF2= MmXLV2FPT0WU
CTB-1 MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjQTWM2OD1yLke3PVU2KM7:TR?= NY\I[Hg1W0GQR1XS
Becker MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\POodKSzVyPUCuO|k3OjFizszN MWfTRW5ITVJ?
KM12 NIX5PIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nQUmlEPTB;MD64OVQ3PiEQvF2= MYfTRW5ITVJ?
ES7 M3:wfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvHWYpSUUN3ME2wMlg6PjVizszN NWnOXpFuW0GQR1XS
COLO-684 M{[yR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwOUC2OVgh|ryP M33ERnNCVkeHUh?=
HCC2998 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLjTWM2OD1yLkmzPFU1KM7:TR?= NH;pdI9USU6JRWK=
TE-10 M4S5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfwb3JpUUN3ME2wMlk3PDNizszN M1v3ZXNCVkeHUh?=
SF126 M37KPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwOUi5O|Eh|ryP NXL6d4RKW0GQR1XS
EKVX NYPUTG1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLvNYw4UUN3ME2xMlA{PDR{IN88US=> NH\CSlRUSU6JRWK=
KARPAS-45 MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nSRmlEPTB;MT6wOFAyPiEQvF2= MnXwV2FPT0WU
KGN MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFwMEWwOFUh|ryP M3\uVnNCVkeHUh?=
ES1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmT6TWM2OD1zLkC3PVIyKM7:TR?= NELCUFFUSU6JRWK=
L-540 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXBTWM2OD1zLkGxPFM6KM7:TR?= Mn[4V2FPT0WU
KURAMOCHI M4TBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHpcmlKSzVyPUGuNVI{PzRizszN NHnKPI1USU6JRWK=
LU-65 NW\YZ3E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXYTWM2OD1zLkGyO|U{KM7:TR?= MUnTRW5ITVJ?
MFH-ino MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS4fFNKSzVyPUGuNVc2ODFizszN NXLOZXhKW0GQR1XS
NCI-H23 MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHBdWJKSzVyPUGuNlA1OSEQvF2= Mm\XV2FPT0WU
IA-LM MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rFOmlEPTB;MT6yOFEyPiEQvF2= MUfTRW5ITVJ?
PSN1 NHHoNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HLTmlEPTB;MT6yO|AyPiEQvF2= M2nNc3NCVkeHUh?=
NCI-H719 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTFwMke0NVEh|ryP NUPr[GY2W0GQR1XS
SW684 NXL2N|YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{npOWlEPTB;MT6yPFY2QSEQvF2= MWPTRW5ITVJ?
HCE-4 NELpdXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPCWnBPUUN3ME2xMlMxOjJzIN88US=> M3u2bHNCVkeHUh?=
EW-16 NIDBWoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPITWM2OD1zLkOxN|Q4KM7:TR?= Mmr2V2FPT0WU
NCI-H128 NGqwW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFwM{W4NVQh|ryP MkPaV2FPT0WU
HC-1 M4nMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzhWopjUUN3ME2xMlM5OTdizszN NGnZcZdUSU6JRWK=
IST-MES1 NGPBUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPsTWM2OD1zLkSwNlA5KM7:TR?= MknOV2FPT0WU
Raji MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTFwNEG4OUDPxE1? NFzzUVFUSU6JRWK=
DMS-114 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEW4OndKSzVyPUGuOFQ2OzlizszN MoXOV2FPT0WU
GI-1 MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fobGlEPTB;MT60O|E{OSEQvF2= MnjWV2FPT0WU
NCI-H2081 NEnrRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFwNUWxPVYh|ryP M{TXT3NCVkeHUh?=
LC-1F NFnC[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVq3epBRUUN3ME2xMlU2OTl6IN88US=> MXfTRW5ITVJ?
NCI-H2227 M3XR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTFwNkG1OlEh|ryP MV3TRW5ITVJ?
D-502MG NVHKS3ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPHTWM2OD1zLk[3NlEyKM7:TR?= Ml61V2FPT0WU
NCI-H2141 NUfvVFByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP4TWM2OD1zLk[3N|E4KM7:TR?= M{HwfnNCVkeHUh?=
LS-411N MnXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXOWpFzUUN3ME2xMlY6QDB5IN88US=> MX;TRW5ITVJ?
SU-DHL-1 M3e2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPrVG94UUN3ME2xMlcyOjhzIN88US=> M2HiTHNCVkeHUh?=
BB30-HNC M2n4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjxTmtKSzVyPUGuO|I3QDVizszN NELVbmtUSU6JRWK=
TE-15 NHy4dZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:4clhKSzVyPUGuPVI{PzNizszN NFjl[ZZUSU6JRWK=
JVM-3 NH;zWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnGb49kUUN3ME2xMlk{QTB2IN88US=> NXG5Z2lSW0GQR1XS
IST-SL2 M1y2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTJwMEGyOVIh|ryP M4nmbnNCVkeHUh?=
EW-18 M1zZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWewcIhMUUN3ME2yMlAzOzN5IN88US=> NUm4NlF1W0GQR1XS
DJM-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzSS49KSzVyPUKuNFI2PTJizszN NYD2WWZvW0GQR1XS
no-11 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TZPGlEPTB;Mj6wN|ExPCEQvF2= NF\1cpJUSU6JRWK=
QIMR-WIL NHvZfWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jGUWlEPTB;Mj6xOlc3OiEQvF2= M17Fd3NCVkeHUh?=
MC-CAR MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPJXoxKSzVyPUKuNlI6PSEQvF2= MnzWV2FPT0WU
KM-H2 NWnET|VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\iTWM2OD1{LkK5NFQ{KM7:TR?= NInXb4VUSU6JRWK=
ECC12 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJwM{e5OEDPxE1? M{LyfHNCVkeHUh?=
HCE-T M1PnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\DTWM2OD1{LkS0PFg{KM7:TR?= NETzRZlUSU6JRWK=
MFM-223 MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJwNUC4O|Eh|ryP M3vTWnNCVkeHUh?=
SW982 MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTZTWM2OD1{LkWxOFgh|ryP NEXUN4xUSU6JRWK=
KG-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\0SWpKSzVyPUKuPFg4QTFizszN NV3IRVZWW0GQR1XS
ES4 MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nTNWlEPTB;Mz6wOlEyOSEQvF2= NV72UFdqW0GQR1XS
SCC-3 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHJPFNuUUN3ME2zMlExQDR6IN88US=> NEfJNGpUSU6JRWK=
RH-1 Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTNwM{i3OFgh|ryP NXjHOWFSW0GQR1XS
NCI-H748 NHzxflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mln4TWM2OD1|LkS0NlY3KM7:TR?= MoTkV2FPT0WU
HCC2218 M1vqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rDSmlEPTB;Mz60Olk{PyEQvF2= Mo\iV2FPT0WU
MEG-01 NF[xOWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fhPWlEPTB;Mz61PVY5KM7:TR?= M2fzdXNCVkeHUh?=
NB12 NUK2SFQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTNwNUm4PFgh|ryP M1TlWnNCVkeHUh?=
SNB75 M{fTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TEe2lEPTB;Mz62NFExOyEQvF2= MoHaV2FPT0WU
KMS-12-PE MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fjVWlEPTB;Mz62O|czOyEQvF2= M1XBVXNCVkeHUh?=
SKM-1 NWHOWZJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjafVRWUUN3ME2zMlcyOzd4IN88US=> NY\veJJvW0GQR1XS
COLO-320-HSR M{\tPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTNwN{W2N|Qh|ryP NXHuXmU{W0GQR1XS
NKM-1 M1e3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;HOGlEPTB;Mz63O|M4QCEQvF2= M3nnUXNCVkeHUh?=
TE-6 M4Drbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HzTmlEPTB;Mz65OFU3OSEQvF2= M2TBNHNCVkeHUh?=
D-336MG NELtdW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITnR|NKSzVyPUSuNFEyPjZizszN MnrxV2FPT0WU
NCI-H1650 MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDVfHFKSzVyPUSuNVU4QTdizszN NIHBN4lUSU6JRWK=
ES3 NVn0[m01T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPVbFdKSzVyPUSuN|I5OjRizszN MV;TRW5ITVJ?
YT M3PhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLETWM2OD12LkO1OFI1KM7:TR?= NX7lT3htW0GQR1XS
ES5 NILWfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTRwNECyOVUh|ryP Mn\EV2FPT0WU
LB647-SCLC M2PKOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlG0TWM2OD12LkW2N|A5KM7:TR?= M1nYbHNCVkeHUh?=
HAL-01 NH\uNZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHYSIhUUUN3ME20MlU4ODN2IN88US=> NYDKfXhmW0GQR1XS
LP-1 Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILvT|FKSzVyPUSuO|I{PzFizszN MULTRW5ITVJ?
BC-1 NXO2TYZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD2TWM2OD13LkCwOFQ4KM7:TR?= M370d3NCVkeHUh?=
EB-3 M4TWbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWr4[IlxUUN3ME21MlA{ODRzIN88US=> MVXTRW5ITVJ?
GT3TKB NEmzUJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnzSlBKSzVyPUWuNVc3PjJizszN NH\EXotUSU6JRWK=
NCI-H209 Mn3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPC[odKSzVyPUWuNVk{PTJizszN MVjTRW5ITVJ?
BT-474 M3zC[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jjfGlEPTB;NT6yN|ExOiEQvF2= MWXTRW5ITVJ?
RKO MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPPToRqUUN3ME21MlI{PDJ{IN88US=> NGDCOJhUSU6JRWK=
SIMA Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTVwM{C3OlUh|ryP MoLHV2FPT0WU
RL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnt[5dKSzVyPUWuN|c2PDFizszN NFmxNYNUSU6JRWK=
GCIY Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTVwNEeyN|Yh|ryP MmD1V2FPT0WU
Calu-6 NV;od3gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2H2d2lEPTB;NT62NlIh|ryP NVG3cHI5W0GQR1XS
ALL-PO NEjiSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofsTWM2OD13Lk[zO|k2KM7:TR?= MWDTRW5ITVJ?
ARH-77 MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTVwNkewPFch|ryP NH3QPG9USU6JRWK=
A4-Fuk MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnNWlRKSzVyPU[uNFgyOThizszN NVTkN3hxW0GQR1XS
NCI-H1581 MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3yRVRKSzVyPU[uNlM5PDlizszN NV;CTZpwW0GQR1XS
HUTU-80 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PCcGlEPTB;Nj6zOlg6PyEQvF2= NFjQNIxUSU6JRWK=
TGW M2\wOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoexTWM2OD14LkS1OVk{KM7:TR?= M{W0dnNCVkeHUh?=
SK-N-FI MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXaTWM2OD14LkS1PFU1KM7:TR?= MWDTRW5ITVJ?
U-266 NXzFRVlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzXTXhKSzVyPU[uOVE6OjZizszN NVrIZmFmW0GQR1XS
EM-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{C0b2lEPTB;Nj62O|A6QSEQvF2= M4nNSnNCVkeHUh?=
NMC-G1 Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTZwN{G4PVUh|ryP M2\ES3NCVkeHUh?=
KASUMI-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLZVY9KSzVyPU[uPFQ4QDdizszN MomzV2FPT0WU
NALM-6 MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDPTWM2OD14Lki2O|U1KM7:TR?= MWfTRW5ITVJ?
OCI-AML2 M4PsdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjiemNKSzVyPUeuNFA{OjZizszN NV\K[GVrW0GQR1XS
SHP-77 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHJWY5KSzVyPUeuNlI1OyEQvF2= NWjIU2JFW0GQR1XS
NOMO-1 M2DJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLjS5NKSzVyPUeuNlQzPTRizszN NYS1O4F1W0GQR1XS
SK-N-DZ MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInKSFJKSzVyPUeuO|ExQDlizszN NVfyWI1wW0GQR1XS
LB1047-RCC NEX5bYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\EUGlEPTB;Nz63NlI{OSEQvF2= MYfTRW5ITVJ?
MZ1-PC Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XDbGlEPTB;Nz64OlU2QCEQvF2= MUPTRW5ITVJ?
NB10 NUTaenhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfRVmZiUUN3ME23Mlk6PTV4IN88US=> NXPkUXNXW0GQR1XS
RL95-2 MnHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfjTWM2OD16LkGwPFQzKM7:TR?= NWLtS4V5W0GQR1XS
OMC-1 NGKwNYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHKT2VKSzVyPUiuOVIyQTFizszN MULTRW5ITVJ?
D-283MED NUHnV3NoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\CNlNvUUN3ME24MlkyPzF7IN88US=> NX\tSZplW0GQR1XS
MC116 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTMPVJmUUN3ME24Mlk4QTRizszN MoX3V2FPT0WU
SJSA-1 M4[3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;UdpdVUUN3ME25MlA6ODlzIN88US=> Mo\GV2FPT0WU
JiyoyeP-2003 NEPmUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3OclNSUUN3ME25MlI6OzF5IN88US=> M3L3c3NCVkeHUh?=
IST-MEL1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\URlRPUUN3ME25Mlc1OTl6IN88US=> NGjzbmNUSU6JRWK=
CTV-1 NGrXRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjmcJRKSzVyPUGwMlA6PzlizszN M4HHXHNCVkeHUh?=
NH-12 Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHmfZlKSzVyPUGwMlI1OzNizszN NYPXdlJ4W0GQR1XS
CA46 NGnPfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i5dmlEPTB;MUCuN|YyKM7:TR?= MoizV2FPT0WU
NCI-SNU-1 M{fZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFyLkS5Olkh|ryP NI\odo9USU6JRWK=
SCLC-21H MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPVT2M3UUN3ME2xNE43PTl4IN88US=> NGTHe2JUSU6JRWK=
EC-GI-10 NIXrTmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFyLkewN|Eh|ryP MUPTRW5ITVJ?
SR NGrYcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M170U2lEPTB;MUGuNFE5PSEQvF2= MXPTRW5ITVJ?
NCI-H1648 NYfkZYZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjFTWM2OD1zMT6wPVY2KM7:TR?= NULEcIgxW0GQR1XS
TGBC1TKB M3LwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfDVZpKSzVyPUGxMlQyODJizszN MWHTRW5ITVJ?
EW-11 NYHnTGJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\UdmlEPTB;MUGuOVE5PiEQvF2= NVH0UXFTW0GQR1XS
SK-MM-2 NVjRbnRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHifWoxUUN3ME2xNU45ODZzIN88US=> MorBV2FPT0WU
NCI-H524 NVnI[nJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7zTWM2OD1zMT65PFIzKM7:TR?= Mn21V2FPT0WU
NOS-1 NEP4eo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlP0TWM2OD1zMj6wN|Q2KM7:TR?= MVvTRW5ITVJ?
AM-38 NUDLWohKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7MTWM2OD1zMj61OlM{KM7:TR?= NHjyNoNUSU6JRWK=
A498 M17Bemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF{LkewOlkh|ryP NXzFbphjW0GQR1XS
KARPAS-422 NWi4VndRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[4cGlEPTB;MUKuO|Q6PiEQvF2= MlHDV2FPT0WU
LU-139 NYG4dmR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDyO4lOUUN3ME2xNk46ODJ4IN88US=> NXLUNVVGW0GQR1XS
COR-L88 Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF{LkmzPFIh|ryP NIfqZ25USU6JRWK=
K5 NEDtb|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jldmlEPTB;MUKuPVQ3OiEQvF2= M4K4OHNCVkeHUh?=
NB13 M2XrPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTF{Lkm3PFMh|ryP MnTiV2FPT0WU
MRK-nu-1 M4nhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfXcHg5UUN3ME2xN{4yQTVizszN MVfTRW5ITVJ?
MHH-NB-11 Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDOTWM2OD1zMz6yPVAzKM7:TR?= MVzTRW5ITVJ?
KU812 M4\TZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\4UIpKSzVyPUGzMlYyOjRizszN M1iyfXNCVkeHUh?=
TE-12 MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;Yb3B{UUN3ME2xN{43QTl2IN88US=> NEm5dGNUSU6JRWK=
NCI-N87 MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4npZ2lEPTB;MUOuO|M3KM7:TR?= MUjTRW5ITVJ?
EB2 MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK2OXM3UUN3ME2xN{45PTB3IN88US=> NIDQOJVUSU6JRWK=
DB M{e1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nGVWlEPTB;MUOuPVg5PSEQvF2= NF[2SmxUSU6JRWK=
697 NUKxVm9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTF2LkS1NVEh|ryP M4nnfHNCVkeHUh?=
MSTO-211H M1r4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXLTWM2OD1zND63OFQ5KM7:TR?= MnPvV2FPT0WU
JVM-2 M4LZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjRTWM2OD1zND63O|M2KM7:TR?= MmfUV2FPT0WU
COLO-824 NUDpcol6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF2Lke5PVQh|ryP NHjLdXZUSU6JRWK=
BC-3 MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2H4WWlEPTB;MUWuN|k5KM7:TR?= M{fGO3NCVkeHUh?=
BOKU NIHMUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLtPJZGUUN3ME2xOU46PjB6IN88US=> NVf6dIk5W0GQR1XS
GOTO NFuxPXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33BVWlEPTB;MU[uPVYyPyEQvF2= MYDTRW5ITVJ?
HCC2157 M4nPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fOZ2lEPTB;MUeuOFc2PSEQvF2= M2faNXNCVkeHUh?=
LS-1034 NVrObIxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[wVFFKSzVyPUG3MlY5OThizszN MX;TRW5ITVJ?
CAL-148 NGTjWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDtTWM2OD1zNz65O|k3KM7:TR?= M{SxSHNCVkeHUh?=
MOLT-4 M3rqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rEb2lEPTB;MUiuPFIxQCEQvF2= NVLCUFA3W0GQR1XS
Daudi MnTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\OOmlEPTB;MUiuPVI{OSEQvF2= MkHEV2FPT0WU
J-RT3-T3-5 NVTPV2E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPqTWM2OD1zOT60NFY3KM7:TR?= NEDYRnNUSU6JRWK=
KMOE-2 NF7US5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH1VlVvUUN3ME2xPU43PDh{IN88US=> NUPsNG5NW0GQR1XS
HL-60 Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXkTWM2OD1{MD6xPVY2KM7:TR?= MkC1V2FPT0WU
P31-FUJ MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D1UWlEPTB;MkCuOFc2OyEQvF2= Ml22V2FPT0WU
IM-9 M1n5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{j5SmlEPTB;MkCuOlIzPCEQvF2= M4rVS3NCVkeHUh?=
HDLM-2 M{m2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXxcFN[UUN3ME2yNE45QDJzIN88US=> MV;TRW5ITVJ?
NCI-H1304 NEe4S4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHVOoRKSzVyPUKxMlA{OTFizszN MYXTRW5ITVJ?
NCI-H345 M{PUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTJzLkC2OFMh|ryP NH3GT4lUSU6JRWK=
RPMI-6666 MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHSTo1KSzVyPUKxMlM3ODJizszN MoOwV2FPT0WU
GR-ST MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPTTWM2OD1{MT60NVch|ryP MlHaV2FPT0WU
CHP-126 NEPaWmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDJUIZKSzVyPUKxMlYyQDFizszN M1jubHNCVkeHUh?=
EHEB M2PlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzoPIc4UUN3ME2yNU43PzNzIN88US=> MojMV2FPT0WU
CPC-N NE\JV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLWOZh4UUN3ME2yOE4xOjBzIN88US=> NIDkOoFUSU6JRWK=
NB1 M1S4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrrNpVGUUN3ME2yOE43QTN7IN88US=> NWHP[Hd6W0GQR1XS
LS-123 NYXqUoZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWSwOlNIUUN3ME2yOE46ODF{IN88US=> MkfXV2FPT0WU
ST486 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfjTWM2OD1{NT6xNVE{KM7:TR?= MXvTRW5ITVJ?
NCI-H1963 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHTOnRKSzVyPUK2MlA3OjNizszN NWTONZMzW0GQR1XS
U-87-MG NVTaU|lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX22OJNHUUN3ME2yOk44PjR2IN88US=> NFrnd4JUSU6JRWK=
COR-L279 NYKzfJZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f1b2lEPTB;Mk[uO|kzOiEQvF2= NHf6fXlUSU6JRWK=
LU-165 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXRXHpOUUN3ME2yPE4xQDZzIN88US=> NWDTZpJrW0GQR1XS
COLO-800 NEPkeZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJ6LkK5OVYh|ryP MnXwV2FPT0WU
ETK-1 M4Lk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3L4c2lEPTB;MkiuN|Q1PiEQvF2= M3W4T3NCVkeHUh?=
LNCaP-Clone-FGC NF3PRXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG1TWM2OD1{OT65NlgyKM7:TR?= NYO4eoxRW0GQR1XS
SIG-M5 Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTRTWM2OD1|MD63PVUzKM7:TR?= MXfTRW5ITVJ?
NB6 NUPzWWw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XyOGlEPTB;M{CuPVUxOyEQvF2= NXPvcIo4W0GQR1XS
NCI-H2107 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnlSmtiUUN3ME2zNU4zOzN6IN88US=> NVHnPZdDW0GQR1XS
SNU-C1 M2XI[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrCTWM2OD1|MT6zNVI3KM7:TR?= NEfERXpUSU6JRWK=
JAR NV3O[W1MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTNzLkO3PVkh|ryP M2jHNHNCVkeHUh?=
L-363 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu2RWVmUUN3ME2zNk4zOTR2IN88US=> M{jQTnNCVkeHUh?=
EW-24 NIiyR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmezTWM2OD1|Mj6zOFc1KM7:TR?= MVLTRW5ITVJ?
NB69 NWn5XY9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTN|Lk[0OVQh|ryP MonHV2FPT0WU
EW-13 NEfZempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2iwV2lEPTB;M{OuPFk3QSEQvF2= M4\SVHNCVkeHUh?=
Ramos-2G6-4C10 NHr1cHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHaZVV2UUN3ME2zOE4zQTl|IN88US=> MoLWV2FPT0WU
TE-11 NH;WZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkj4TWM2OD1|ND60PFIzKM7:TR?= NUnlV41TW0GQR1XS
L-428 NGG2R|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTN2Lke1N|Yh|ryP MYfTRW5ITVJ?
KP-N-YN NYrZfVd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{S4ZWlEPTB;M{SuPVA2PyEQvF2= NU\QbmFbW0GQR1XS
CGTH-W-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[xTWM2OD1|Nj65NFQ5KM7:TR?= MkPKV2FPT0WU
K-562 NGTkU3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTN5LkC4OlQh|ryP M1nw[3NCVkeHUh?=
NCI-H1299 M2XZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljQTWM2OD1|OD6xOlA{KM7:TR?= M1;GdnNCVkeHUh?=
RCC10RGB MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLuTWM2OD1|OD6yNFg{KM7:TR?= NXfoTphSW0GQR1XS
NCI-SNU-16 NHTDO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInae3hKSzVyPUO4MlU3PTNizszN MofHV2FPT0WU
LC-2-ad NH;2dXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTN7LkSzN|ch|ryP NInyfllUSU6JRWK=
MHH-PREB-1 M2[1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTN7LkezPFgh|ryP NInQTWpUSU6JRWK=
NCI-H64 MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fmUmlEPTB;NECuNFk1QCEQvF2= M4Tjd3NCVkeHUh?=
LB996-RCC NU\RO3J2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFraZpVKSzVyPUSwMlg4OTZizszN MmDzV2FPT0WU
DEL MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTRzLkS0NFUh|ryP MXHTRW5ITVJ?
MLMA MmPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\XTWM2OD12MT63OVk2KM7:TR?= NYP1cnl{W0GQR1XS
SBC-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\qU5ZXUUN3ME20Nk4yQDB4IN88US=> M{foTXNCVkeHUh?=
MPP-89 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjHNYJKSzVyPUSyMlU5PzVizszN M3v6UXNCVkeHUh?=
MV-4-11 M1zremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYm2e5NIUUN3ME20Nk46ODZ5IN88US=> M3\KbXNCVkeHUh?=
EoL-1- M37IW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETRXZZKSzVyPUS0MlE2PjhizszN NV;HOGptW0GQR1XS
CW-2 M1v6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTkVW5KSzVyPUS0Mlg{PDJizszN M17CPXNCVkeHUh?=
HT NWPQWoZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\oSmNMUUN3ME20OU44ODB5IN88US=> M2nscnNCVkeHUh?=
SW954 MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\CNW9KSzVyPUS3MlQyOjhizszN M4PSXXNCVkeHUh?=
A3-KAW Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTCcXVKSzVyPUS5MlgxPjFizszN NUHnToUyW0GQR1XS
TC-YIK M1nKfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjG[5lKSzVyPUWwMlA{PjNizszN MlW1V2FPT0WU
SW962 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTV2LkizOVch|ryP MlOzV2FPT0WU
KP-N-RT-BM-1 MoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjGfnZKSzVyPUW2MlY3OzhizszN MXjTRW5ITVJ?
NCI-H1395 M2TPfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUftdYRLUUN3ME21PE45OTd{IN88US=> MUDTRW5ITVJ?
RPMI-8402 NFjBNFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jCSmlEPTB;NUiuPVUzPiEQvF2= NFXMd2xUSU6JRWK=
SCH NEfwWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fscWlEPTB;NkCuPVY{QCEQvF2= NFqzT2xUSU6JRWK=
NCI-H2196 NY\Jb|ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfGZo1KSzVyPU[xMlI{OSEQvF2= NHfvNGZUSU6JRWK=
LOXIMVI NYf4RZJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHscW9KSzVyPU[xMlgzPjZizszN MoXRV2FPT0WU
TGBC24TKB M3\YV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXm1bllHUUN3ME22Nk4yPDlzIN88US=> MorzV2FPT0WU
SK-MEL-2 MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml35TWM2OD14Mz65PFkzKM7:TR?= MlLXV2FPT0WU
U-698-M MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTZ6LkW2PFch|ryP M1zYWHNCVkeHUh?=
NCI-H1522 NH:xbItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjENmg3UUN3ME22PU4xODR5IN88US=> NVTHV3VFW0GQR1XS
UACC-812 NH3lc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGC3NVJKSzVyPU[5MlUzODlizszN Ml\1V2FPT0WU
MHH-CALL-2 Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfXbVJZUUN3ME23NE4xPiEQvF2= NILKTZVUSU6JRWK=
NB5 NXXHSHRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTdyLkO0Olgh|ryP M4rCdnNCVkeHUh?=
KARPAS-299 NUDyUo5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\ZUGdKSzVyPUewMlQ1PDdizszN Ml7wV2FPT0WU
NCI-H1694 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlq1TWM2OD15MT6wN|Ih|ryP M4PIfnNCVkeHUh?=
NCI-H82 MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTdzLkm1NFch|ryP NF7rW5ZUSU6JRWK=
SCC-15 M2DHbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XoOWlEPTB;N{KuN|Qh|ryP NVHFUHlwW0GQR1XS
NCI-H1436 MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXqTWM2OD15Mj63OFU3KM7:TR?= NFnLbJZUSU6JRWK=
ATN-1 M3vub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTd2LkWwOUDPxE1? M1zlUXNCVkeHUh?=
RPMI-8866 MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3YS2x4UUN3ME23OE44PTB7IN88US=> M2GxR3NCVkeHUh?=
HCC1599 MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVK4PY1iUUN3ME23OE45PzN{IN88US=> M2X6XnNCVkeHUh?=
NCI-H1155 MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G4SWlEPTB;N{SuPVM3PyEQvF2= M4rxXXNCVkeHUh?=
DOHH-2 M4P0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPYTWM2OD15ND65OVE1KM7:TR?= NIL5dVBUSU6JRWK=
SK-NEP-1 M3TROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTd3LkC3OVQh|ryP NGDoRXhUSU6JRWK=
HCC1187 NHn4XVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTd5Lk[xNlIh|ryP NVrFOW82W0GQR1XS
NCI-H322M MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\Q[WlEPTB;N{iuN|cxQSEQvF2= NWO5Tlh4W0GQR1XS
NCI-H526 NEjsS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\VZWFKSzVyPUe4MlU5PzdizszN Mk[xV2FPT0WU
NCI-H2171 NGTNT|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37BXmlEPTB;N{muOFE{PiEQvF2= MX\TRW5ITVJ?
COLO-668 NYfp[oxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRThzLkW4PFQh|ryP MXHTRW5ITVJ?
RS4-11 M1nKdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHPWIxzUUN3ME24Nk4zPTB3IN88US=> MmnzV2FPT0WU
NCI-H716 M4PFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHvVIdKSzVyPUiyMlkxPzVizszN NULVN4JiW0GQR1XS
LU-134-A NF3WXW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK5d4tKSzVyPUizMlE{PTFizszN NFPsOodUSU6JRWK=
RPMI-8226 NFq3dVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDGPHdUUUN3ME24OE4zOTB5IN88US=> MYfTRW5ITVJ?
KY821 NEO0RlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV2zWXQ5UUN3ME25NU43PTVzIN88US=> M4m2OnNCVkeHUh?=
ECC4 Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTl|LkiyOlkh|ryP NG[3UYhUSU6JRWK=
EW-3 NV\IW2R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTl2LkmwPFEh|ryP MWDTRW5ITVJ?
NB7 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[xeI9KSzVyPUm1Mlc4QDZizszN NEH6W2RUSU6JRWK=
NCI-H720 MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnPUGZjUUN3ME25PE41ODZzIN88US=> NG\YRpJUSU6JRWK=
NCI-H446 NIjURlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;ybHJKSzVyPUm5Mlc2QDhizszN MX\TRW5ITVJ?
NCI-H889 Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjEbHRKSzVyPUGwOE4zPDJizszN MnzXV2FPT0WU
EW-22 MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXRNlRKSzVyPUGwOk4yQSEQvF2= MWHTRW5ITVJ?
BV-173 NFS1ZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7udFlKSzVyPUGwPE44OjhizszN NXTxTIh5W0GQR1XS
WSU-NHL M4jUUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TBSmlEPTB;MUC5MlY4OSEQvF2= NHTlV|NUSU6JRWK=
MN-60 NVi4bpEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPuV21FUUN3ME2xNFkvPjlizszN MmD2V2FPT0WU
DG-75 M2S3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFzMz6zOVIh|ryP M2HTNHNCVkeHUh?=
DMS-79 MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFzNz6zPFIh|ryP NHHHTnBUSU6JRWK=
SK-MEL-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorDTWM2OD1zMUiuNFA6KM7:TR?= M4DYUXNCVkeHUh?=
DMS-153 NGT3[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjpXHVKSzVyPUGyNU44PDVizszN NYX1fXcxW0GQR1XS
NCI-H510A M1LNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;DTWM2OD1zMkeuN|Ih|ryP M2jJVHNCVkeHUh?=
BE-13 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLaeFFKSzVyPUGzOE4xPDRizszN Mn\MV2FPT0WU
KP-N-YS NILHZ4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vYZWlEPTB;MUO5Mlc{PiEQvF2= NFztR4pUSU6JRWK=
SUP-T1 MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[yUnp3UUN3ME2xOFMvPzB6IN88US=> NGnnfHpUSU6JRWK=
EW-12 NWHMeG5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTF2ND62PVkh|ryP MWTTRW5ITVJ?
NB14 MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe4dplKSzVyPUG0O{4xQDJizszN MnjYV2FPT0WU
MDA-MB-134-VI M{jHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXLZWw3UUN3ME2xOFgvOjZ6IN88US=> Mn;OV2FPT0WU
NCI-H1770 NHT0XYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmi0TWM2OD1zNU[uNlc6KM7:TR?= M4HVVXNCVkeHUh?=
TUR MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTvTWM2OD1zNkeuPFch|ryP MmTMV2FPT0WU
NCI-H1417 NXfLO|h7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLYcpFKSzVyPUG4NE4{OzFizszN M2XVZnNCVkeHUh?=
IMR-5 NGXXb|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jteGlEPTB;MUixMlU4OSEQvF2= NVm2cYQ5W0GQR1XS
NCI-H226 NYPOSoZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEiyNm9KSzVyPUG4PE45PjZizszN M3T3S3NCVkeHUh?=
NCI-H187 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzrWZZKSzVyPUG5NE4xPjRizszN MkjWV2FPT0WU
SF539 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrMUZFQUUN3ME2xPVIvPzJ6IN88US=> NXHEOmt4W0GQR1XS
TALL-1 MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PofmlEPTB;MUm4MlMxPCEQvF2= MXPTRW5ITVJ?
TE-441-T MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLCeZpKSzVyPUG5PU44OzlizszN MUDTRW5ITVJ?
REH NEXYenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJ|Nj62NlYh|ryP NWnmXodqW0GQR1XS
MS-1 M4HlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfY[VQ3UUN3ME2yN|kvOTJzIN88US=> NWLyNodbW0GQR1XS
THP-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJ4ND63N|gh|ryP NELIW2lUSU6JRWK=
NCI-H1838 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jldGlEPTB;MkexMlQ2PiEQvF2= NYLr[GtbW0GQR1XS
P30-OHK NX;uTZlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJ6Mz64OFch|ryP NXj6UIx3W0GQR1XS
C8166 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknJTWM2OD1|NEWuN|M5KM7:TR?= NWW5UIdvW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo試験 Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]
臨床試験
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Measurement of inhibitory activities of MG-132 against 20S proteasome The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.

細胞アッセイ:

[3]

細胞株 KIM-2, HC11, and ES
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 24, and 48 hours
実験の流れ

Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.

動物実験:

[7]

動物モデル Male mdx (C57BL/10ScSn DMD mdx) mice
製剤 Dissolved in DMSO, and diluted in PBS
投薬量 ~10 μg/kg/day
投与方法 Injection

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download MG-132 SDF
分子量 475.62
化学式

C26H41N3O5

CAS No. 133407-82-6
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 95 mg/mL (199.73 mM)
エタノール 95 mg/mL (199.73 mM)
<1 mg/mL (<1 mM)
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 benzyl (S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate

カスタマーフィードバック (9)


Click to enlarge
Rating
Source Nat Cell Biol, 2015, 17(1), 95-103. MG-132 purchased from Selleck
Method Immunoprecipitation
Cell Lines MDA-MB-231 cells
Concentrations 10 uM
Incubation Time 6 h
Results SIAH2 destabilizes LATS2 through proteasome. SIAH2-mediated LATS2 degradation was inhibited by proteasomal inhibitor MG132, but not by lysosomal inhibitor BA-1. The half-life of LATS2 was shortened by SIAH2.

Click to enlarge
Rating
Source Nucleic Acids Res, 2014, 42(1), 458-74. MG-132 purchased from Selleck
Method Western blot
Cell Lines HeLa cells
Concentrations 20 uM
Incubation Time 8 h
Results As RMND5A downregulation resulted in a rapid decrease of protein Exportin-5, this effect was partially abolished by the proteasome inhibitor MG132, indicating that RMND5A protect Exportin-5 protein against proteasome degradation.

Click to enlarge
Rating
Source Nucleic Acids Res, 2014, 42(1), 458-74. MG-132 purchased from Selleck
Method Immunocytochemistry
Cell Lines HeLa cells
Concentrations 20 uM
Incubation Time 8 h
Results It was surprised to observe that Exportin-5 retention in nucleus when its protein levels were downregulated by RMND5A siRNA or miR-138. The proteasome inhibitor MG132 could recover not only Exportin-5 protein levels but also its normal subcellular localization.

Click to enlarge
Rating
Source EMBO Mol Med, 2013, 5, 397-412. MG-132 purchased from Selleck
Method Western Blot
Cell Lines MEF cells
Concentrations 30 uM
Incubation Time 6 h
Results Treatment of MEF with proteasome inhibitor MG132 resulted in similar increase of steady state levels of intracellular ATZ in both GFP- and TFEB- transfected Cells.

Click to enlarge
Rating
Source Cell Rep, 2015, 11(9), 1458-73. MG-132 purchased from Selleck
Method Western Blot
Cell Lines A375, Lu1205 cells
Concentrations 5 uM
Incubation Time 10 h
Results MG132 treatment increased JAK1 steady-state levels, masking the effect of RNF125 depletion and partially blocking deregulated JAK1 expression by ectopically expressed RNF125.

Click to enlarge
Rating
Source Plant Physiol, 2012, 60(1), 118-34. MG-132 purchased from Selleck
Method Immunoblot analysis
Cell Lines Arabidopsis thaliana
Concentrations 100 uM
Incubation Time 12 h
Results These rates of loss were markedly slower in the lrb1-1 lrb2-1 background. Importantly, phyB breakdown was also substantially attenuated upon exposing wild-type seedlings to the proteasome inhibitor MG132, thus implicating the 26S proteasome in particular. MG132 treatment also slightly stabilized phyB levels in lrb1-1 lrb2-1 seedlings, implying that other factors besides LRB1 and LRB2 might also direct phyB breakdown.

Click to enlarge
Rating
Source Toxicol Appl Pharmacol, 2015, 286(2), 135-41. MG-132 purchased from Selleck
Method Immunofluorescence
Cell Lines γ-H2AX-stained cells
Concentrations 100 uM
Incubation Time 3 h
Results G2 cell cycle arrest usually reflects the formation of genomic damage in the preceding S-phase, which activates checkpoint response upon the entry of cells into G2 phase. Furthermore, MG132-treated cells also had larger amounts of γ-H2AX, as evidenced by the increased staining in individual nuclei .

Click to enlarge
Rating
Source FEBS Lett, 2012, 586, 3787–3792. MG-132 purchased from Selleck
Method Western Blot
Cell Lines Hela cells
Concentrations
Incubation Time 12 h
Results When GSK-3 (Ser9) degradation was blocked by proteasome inhibitor (MG132), the increased amount of phosphorylated GSK-3 (Ser9) in responding to NOK was more clearly observed in the HeLa-NOK-HA cells (Fig. C).

Click to enlarge
Rating
Source 2012, Dr. Edison DUKE-NUS Graduate Medical School Singapore.. MG-132 purchased from Selleck
Method Western blot
Cell Lines NIH3T3 cells
Concentrations 25 μM
Incubation Time 1-4 h
Results By adding MG132, a proteasome inhibitor, the degradation of Per2 was dramatically decreased within 4 hours treatment.

文献中の引用 (43)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related プロテアソーム 阻害剤

  • VR23

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat(BB-2516)

    Marimastat (BB-2516)が、幅広いスペクトルマトリックス・メタロプロテアーゼ(MMP) MMP-9、MMP-1、MMP-2、MMP-14とMMP-7のための阻害剤です。

  • Ledipasvir (GS5885)

    Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.

  • Bortezomib (PS-341)

    Bortezomib (PS-341)は、強力なプロテアソーム阻害剤で、Kiが0.6nMです。

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is a proteasome inhibitor with IC50 less than 5 nM.

  • Ixazomib (MLN2238)

    Ixazomib (MLN2238)は窒素端加帽の二ペプチドロイシンホウ酸で、20Sプロテアソームのカイモトリプシン類(β5)加水分解部位を抑制、IC50が3.4nM、Ki値が0.93nM。

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914(PR-957)は、恒常的プロテアソームのための最小限の交差反応性を持つ強力かつ選択的な免疫プロテアソームの阻害剤です。

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • MLN9708

    MLN9708は二代目経口生物の有効性にプロテアソーム選択阻害剤で、20Sプロテアソームのカイモトリプシン類(β5)加水分解部位に作用すると、IC50が3.4nM、Ki値が0.93nMになる。

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

最近チェックしたアイテム

Tags: MG-132を買う | MG-132供給者 | MG-132を購入する | MG-132費用 | MG-132生産者 | オーダーMG-132 | MG-132代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ